surmount-1 tirzepatide weight loss non-diabetic π Could a new medication help reduce complications of obesity? The SURMOUNT-MMO trial investigates tirzepatide, a dual GIP and GLP-1 receptor agonist, in adults with obesity or overweight but without diabetes. Researchers Read now: The SURPASS-EARLY trial
Pay in 4 interest-free payments of $6.82 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours Β· Estimated delivery Aug 12 - Aug 17










:max_bytes(150000):strip_icc()/VWH-GettyImages-2276706586.jpg-4e49ad1f948143ed99767b89bf0289d7.jpg)











